Universal Beteiligungs und Servicegesellschaft mbH Takes Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 20,141 shares of the company's stock, valued at approximately $1,091,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of MLTX. PNC Financial Services Group Inc. boosted its stake in MoonLake Immunotherapeutics by 3.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 8,500 shares of the company's stock worth $460,000 after buying an additional 320 shares during the period. Deutsche Bank AG boosted its stake in shares of MoonLake Immunotherapeutics by 59.8% during the fourth quarter. Deutsche Bank AG now owns 903 shares of the company's stock valued at $49,000 after purchasing an additional 338 shares during the period. Geode Capital Management LLC raised its holdings in shares of MoonLake Immunotherapeutics by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 58,950 shares of the company's stock valued at $3,192,000 after acquiring an additional 540 shares in the last quarter. DnB Asset Management AS raised its holdings in shares of MoonLake Immunotherapeutics by 11.3% in the fourth quarter. DnB Asset Management AS now owns 8,356 shares of the company's stock valued at $452,000 after acquiring an additional 847 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in shares of MoonLake Immunotherapeutics by 18.4% in the fourth quarter. Teacher Retirement System of Texas now owns 6,532 shares of the company's stock valued at $354,000 after acquiring an additional 1,013 shares in the last quarter. 93.85% of the stock is owned by hedge funds and other institutional investors.

MoonLake Immunotherapeutics Stock Down 4.0%

Shares of MLTX traded down $1.95 during mid-day trading on Friday, hitting $46.88. 881,415 shares of the company traded hands, compared to its average volume of 378,396. MoonLake Immunotherapeutics has a 1-year low of $31.42 and a 1-year high of $58.26. The company has a market capitalization of $3.00 billion, a PE ratio of -36.34 and a beta of 1.23. The business has a 50 day moving average of $39.15 and a 200 day moving average of $43.87.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.13. During the same quarter last year, the company posted ($0.22) EPS. As a group, research analysts expect that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Analysts Set New Price Targets

MLTX has been the subject of several recent research reports. HC Wainwright restated a "buy" rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Thursday, February 27th. The Goldman Sachs Group reduced their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Needham & Company LLC reiterated a "buy" rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Wedbush reiterated an "outperform" rating and issued a $80.00 target price (up from $78.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $67.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday. Eight analysts have rated the stock with a buy rating, According to MarketBeat, MoonLake Immunotherapeutics presently has a consensus rating of "Buy" and an average price target of $78.71.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.